Drug Database
Back to search

United States· US:0003-3756_1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce

OPDIVO

A nivolumab product containing nivolumab, registered in United States by E.R. Squibb & Sons, L.L.C.. The same ATC class is registered in 13 of our 19 countries.

ATC L01FF01

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedOPDIVOATCL01FF01REGISTER NO.US:0003-3756_1fce9e6a…PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nivolumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nivolumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FF01 (nivolumab), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 8 of them publish a price we can compare per daily dose
Search nivolumab products by name

Nivolumab · ATC L01FF01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
NIVOLUMAB
Manufacturer
E.R. Squibb & Sons, L.L.C.
Country
United States (US)
ATC code
L01FF01
ATC class
Nivolumab
Defined daily dose
17.1 mg, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    0003-3756-14

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

22 interactions on record for nivolumab.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check nivolumab against other medicinesHow interaction checks work

Nivolumab · interactions on record

22 records

  • 3 severe
  • 19 moderate

Most severe, free to view

  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • PomalidomideL04AX06severe
  • PrednisoloneA07EA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nivolumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nivolumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Opdivo
  • Liechtenstein · Opdivo
  • Norway · Opdivo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1f4076c4-8ad6-42c8-9b18-077e427893e3
GET /v1/drugs/1f4076c4-8ad6-42c8-9b18-077e427893e3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "INTRAVENOUS",
  "source": "ndc",
  "strength": "10",
  "substance": "NIVOLUMAB",
  "productndc": "0003-3756",
  "dosage_form": "INJECTION",
  "dea_schedule": null,
  "strength_unit": "mg/mL",
  "application_number": "BLA125554",
  "marketing_category": "BLA"
}
API referenceMCP serverPlans

See everything about nivolumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console